Clinical Research Associate (CRA)
ROLE DEFINITION & RESPONSIBILITIES
A Clinical Research Associate (CRA), or Clinical Monitor, serves as the primary liaison between trial sponsors/CROs and clinical study sites. CRAs ensure clinical trials are conducted in strict compliance with the study protocol, Good Clinical Practice (ICH-GCP E6 R2/R3), and regulatory standards through Pre-Study, Site Initiation, Interim Monitoring, and Close-Out visits.
SALARY INTELLIGENCE ROADMAP
LEARNING PATHWAYS
Clinical Trial Methodology & Ethics
Master the Declaration of Helsinki, Belmont Report, ICH-GCP E6, and patient informed consent protocols.
Site Monitoring Visit Procedures
Learn end-to-end execution of Site Selection (PSSV), Initiation (SIV), Interim Monitoring (IMV), and Site Close-Out (COV).
Trial Master File (TMF) & Regulatory Audits
Manage essential trial documentation according to the DIA TMF Reference Model.
Investigational Product & Lab Logistics
Verify temperature logs, drug accountability records, dispensation logs, and biological sample shipping.
CONNECTED ZANE PROED ACADEMY COURSES
Clinical Research & GCP Standards Masterclass
Become certified under international ICH-GCP regulatory parameters.
VERIFIED INTERVIEW PREPARATION
> Q: What is Source Data Verification (SDV) and how does Risk-Based Monitoring (RBM) change traditional SDV?
SDV is the process by which data recorded on the Case Report Form (CRF) is compared against original patient hospital records, lab printouts, and doctor notes to confirm data integrity. Under Risk-Based Monitoring (ICH-GCP E6 R2), 100% SDV is replaced by targeted, centralized statistical monitoring focusing on critical data points like primary efficacy endpoints, safety events, and informed consent compliance.
> Q: What steps must a CRA take when discovering an unreported Serious Adverse Event during a routine monitoring visit?
1) Verify source documents and confirm date of onset. 2) Immediately alert the Principal Investigator (PI) of the regulatory breach. 3) Ensure the PI reports the SAE to the sponsor within 24 hours. 4) Document the protocol deviation in the monitoring visit report and issue a formal Corrective and Preventive Action (CAPA) plan.